Shijiazhuang Yiling Pharmaceutical (002603.SZ) Subsidiary's Drug Clinical Trial Application for Jiangu Joint Granules Accepted
Yiling Pharmaceutical (002603.SZ) announced that its wholly-owned subsidiary Beijing Yiling Pharmaceutical Co., Ltd. received the Notice of Acceptance issued upon approval by the National Medical Products Administration on October 21, 2026, and the new drug clinical trial application for Jiangu Joint Granules has been accepted. The proposed indications for Jiangu Joint Granules are: tonifying the kidney and strengthening bones, promoting blood circulation and dredging collaterals, and relaxing sinews and relieving pain.
Shijiazhuang Yiling Pharmaceutical (002603.SZ) issued an announcement that its wholly-owned subsidiary Beijing Shijiazhuang Yiling Pharmaceutical Co., Ltd. received on October 21, 2026 the "Notice of Acceptance" approved and issued by the National Medical Products Administration, and the new drug clinical trial application for Jiangu Joint Granules has been accepted. The proposed indications for Jiangu Joint Granules are: tonifying the kidney and strengthening bones, promoting blood circulation and dredging collaterals, and relaxing sinews and relieving pain.
Related Articles
CHINA STARCH (03838) repurchased 13 million shares for HK$2.2 million on October 22.
LUK FOOK HOLD (00590) overall retail value grew 8% year-on-year in the second quarter.
NATIONAL ELEC H (00213) repurchased 30,000 shares on October 22 for HK$10,800.
CHINA STARCH (03838) repurchased 13 million shares for HK$2.2 million on October 22.
LUK FOOK HOLD (00590) overall retail value grew 8% year-on-year in the second quarter.
NATIONAL ELEC H (00213) repurchased 30,000 shares on October 22 for HK$10,800.
